[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.

Acute Myeloid Leukemia - Therapy, excluding Transplantation: Poster III

Program: Oral and Poster Abstracts
Type: Poster
Monday, December 6, 2010: 6:00 PM-8:00 PM
Hall A3/A4 (Orange County Convention Center)
Inhibitor of the CREB Proto-Oncogene Suppresses AML Cell Proliferation and Induces Apoptosis In Vitro and In Vivo

Bryan Mitton, M.D., Ph.D.1*, Alan Ikeda1*, Kazunari Yamada, M.D., Ph.D.2*, Bingbing Li, Ph.D.3*, Qiuhua Fan, Ph.D.3*, Elliot Landaw, M.D., Ph.D.4*, Xiangshu Xiao, Ph.D.3* and Kathleen M Sakamoto, MD, PhD5

1Pediatric Hematology/Oncology, University of California Los Angeles, Los Angeles, CA
2David Geffen School of Medicine at UCLA, Los Angeles, CA
3Physiology and Pharmacology, Oregon Health & Science University, Portland, OR
4Biomathematics, David Geffen School of Medicine at UCLA, Los Angeles, CA
5Pediatrics, David Geffen School of Medicine, UCLA, Los Angeles, CA

Poster Board Number: III-49
Preclinical Development of Triptolide Derivative MRx102 as a Therapeutic Agent for Acute Myeloid Leukemia

John M. Fidler, Ph.D.1*, Jinhua An, Ph.D.1*, John H. Musser, Ph.D.1*, Duncan H. Mak, M.S.2*, Bing Carter, Ph.D.3 and Michael Andreeff, MD, PhD4

1MyeloRx LLC, Vallejo, CA
2Stem Cell Transplantation Research, MD Anderson Cancer Center, Houston, TX
3Molecular Hematology & Therapy, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
4Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX

Poster Board Number: III-50
Cyclic Administration of Combination of Sorafenib and Vorinostat In Poor-Risk AML: A Pharmacodynamically-Oriented Extended Phase I Trial

Hamid Sayar, MD1*, Larry Cripe, MD2*, Mary Cangany1*, Jill Weisenbach, RN, OCN3*, Katie J. Sargent, RN1*, Chirayu Goswami, PhD.4*, Lang Li, PhD.4*, Annique Wilson-Weekes, MS1*, Rajasubramaniam Shanmugam, PhD1* and H. Scott Boswell, MD5

1Hematology-Oncology, Indiana Cancer Research Institute, Indianapolis, iN, IN
2Indiana University Cancer Center, Indianapolis, IN
3Suite 311, Indiana University Cancer Center, Indianapolis, IN
4Center for Computational Biology, Indiana University School of Medicine, Indianapolis, iN, IN
5Hematology-Oncology, VA Medical Center, Indianapolis, iN, IN

Poster Board Number: III-51
Phase 2 Study of MLN8237, An Investigational Aurora A Kinase (AAK) Inhibitor In Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Stuart L Goldberg, MD1, Pierre Fenaux, MD, PhD2, Michael D Craig, MD3, Emmanuel Gyan, MD, PhD4*, John Lister, MD5, Jeannine Kassis, MD6, Arnaud Pigneux, MD, PhD7*, Gary J Schiller, MD8, JungAh Jung, PhD9*, E. Jane Leonard, MSc9*, Howard Fingert, MD9* and Peter Westervelt, MD, PhD10*

1John Theurer Cancer Center Hackensack University Medical Center, Hackensack, NJ
2Service d'hématologie Clinique, Hôpital Avicenne (AP-HP)/Université, Paris 13, Bobigny, France
3Mary Babb Randolph Cancer Center, West Virginia University School of Medicine, Morgantown, WV
4Service d'hématologie et Thérapie Cellulaire, CHRU de Tours, France
5Division of Hematology/Oncology, Western Pennsylvania Cancer Institute, Pittsburgh, PA
6University of Montreal, Montreal, QC, Canada
7Service d'hématologie CHU Bordeaux, Pessac, France
8University of California Los Angeles, Los Angeles, CA
9Millennium Pharmaceuticals, Inc., Cambridge, MA
10Division of Oncology, Washington University Medical School, St. Louis, MO

Poster Board Number: III-52
Caffeic Acid Phenetyl Ester, a Brazilian-Green-Propolis Derivative, Induces apoptosis in AML Cells, Promotes up Regulation of G-Protein Signaling and Hyper Secretion of IL-8

Priscila S Scheucher, Ph.D1*, Guilherme A dos Santos2*, Hamilton L Gimenes Teixeira2*, Carolina H Thomé3*, Antonio R Lucena-Araujo2*, Roberto P. Falcao, MD, PhD2 and Eduardo M. Rego, MD, PhD2

1Internal Medicine, Medical School of Ribeirao Preto, Ribeirao Preto, Brazil
2Clinical Medicine, Ribeirao Preto Medical School of University of Sao Paulo, Ribeirao Preto, Brazil
3Biochemistry, UNIFESP Medical School, Sao Paulo, Brazil

Poster Board Number: III-53
Inhibition of Histone Deacetylases 1 and 6 Enhances Ara-C-Induced Apoptosis In Pediatric Acute Myeloid Leukemia Cells

Xuelian Xu1*, Chengzhi Xie1*, Holly Edwards1*, Hui Zhou2*, Steven Buck, MS3*, Larry Matherly, PhD4, Jeffrey Taub, MD5 and Yubin Ge, PhD6

1Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI
2College of Life Science, Jilin University, Changchun, China
3Division of Hematology/Oncology, Children's Hosptial of Michigan, Detroit, MI
4Barbara Ann Karmanos Cancer Inst., Detroit, MI
5Children's Hosp. of Michigan, Detroit, MI
6Wayne State Univ., Karmanos Cancer Institute, Detroit, MI

Poster Board Number: III-54
Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined Wtih Topoecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias 

Judith E. Karp, MD1, Keith W Pratz, MD2, Mark R. Litzow, MD3, Jiuping Ji, PhD4*, Alice Chen, MD5*, Michelle Rudek, PharmD, PhD6* and Scott H. Kaufmann, MD, PhD7

1Department of Oncology, Division of Hematological Malignancies, Sidney Kimmel Comprehensive Cancer Center at John Hopkins , Baltimore, MD
2Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
3Hematology, Mayo Clinic, Rochester, MN
4Investigational Drug Branch, National Cancer Institute, Bethesda, MD
5IDB/CTEP/NCI, National Cancer Institute, Rockville, MD
6Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
7Oncology Research, Mayo Clinic, Rochester, MN

Poster Board Number: III-55
A Novel Direct STAT3 Inhibitor OPB-31121 Induces Tumor-Specific Growth Inhibition In a Wide Range of Hematopoietic Malignancies and Effectively Suppresses the Chemotherapy Resistant Quiescent Cells In Vivo

Fumihiko Hayakawa, MD, PhD1*, Keiki Sugimoto1*, Shingo Kurahashi, MD, PhD1*, Hironori Matsuyama2*, Yasuo Harada2*, Norikazu Hashimoto2*, Naoto Ohi2*, Takeshi Kodama2*, Takumi Sumida, DVM2*, Tomohiro Kinoshita, MD, PhD1 and Tomoki Naoe, MD, PhD1

1Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
2Fujii Memorial Research Institute, Otsuka Pharmaceutical Co., Ltd., Otsu, Japan

Poster Board Number: III-56
Differential Dependence On Wnt Signaling Allows Chemical Mediated Eradication of Human Acute Leukemia without Affecting Normal Blood Stem Cells

Ruth M. Risueño, PhD1*, Eva Szabo, PhD1*, Uyen Maria Dang, BSc2*, Marilyne Levadoux-Martin, PhD1*, Jae-Uk Chung3*, Anargyros Xenocostas, MD, FRCPC4, Brian Leber, MD5 and Mickie Bhatia, PhD6*

1Stem Cell and Cancer Research Institute, Hamilton, ON, Canada
2Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada
3Central Research Institute, Choongwae Pharma Corp., Hwaseong, South Korea
4Department of Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada
5McMaster Univ. Medical Centre, Hamilton, ON, Canada
6McMaster University, Michael G. DeGroote School of Medicine, Hamilton, ON, Canada

Poster Board Number: III-57
CHR-2845, a Monocyte/Macrophage Targeted Histone Deacetylase Inhibitor In a First In Man Clinical Trial In Subjects with Advanced Haematological Malignancies

Gert Ossenkoppele, MD, PhD1, Bob Lowenberg, MD, PhD2, Pierre Zachee, MD, PhD3, Norbert Vey4, Dimitri A. Breems, MD, PhD3, Arjan A. Van de Loosdrecht, MD, PhD1, Phillip Debnam, PhD5*, Lindsey Needham, PhD5*, Lindsay Bawden, PhD5* and Leon Hooftman, MD5*

1VU University Medical Center, Amsterdam, Netherlands
2Erasmus University Medical Center, Rotterdam, Netherlands
3ZNA Stuivenberg, Antwerp, Belgium
4Inst. Paoli-Calmettes, Marseille, France
5Chroma Therapeutics Ltd, Oxford, United Kingdom

Poster Board Number: III-58
In Vivo Treatment of AML Patients with High-Dose Simvastatin Inhibits Geranylgeranylation In AML Cells

Karen van der Weide1*, Susan D.P.W.M. de Jonge-Peeters1*, Gerwin A. Huls, MD, PhD1*, Rudolf S.N. Fehrmann2*, Jan J. Schuringa, PhD1, Folkert Kuipers, PhD3*, Elisabeth G.E. de Vries, MD, PhD2* and Edo Vellenga, MD, PhD4

1Department of Hematology, University Medical Center Groningen, Groningen, Netherlands
2Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands
3Department of Pediatrics, University Medical Center Groningen, Groningen, Netherlands
4University Hospital Groningen, Groningen, Netherlands

Poster Board Number: III-59
GSK1120212, a MEK1/MEK2 Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity In a Dose Rising Trial In Subjects with AML and Other Hematologic Malignancies

Gautam Borthakur1, James M. Foran, MD, FRCPC2, Tapan Kadia, MD1, Elias Jabbour, MD1, Paul Wissel, MD3*, Donna Cox, PhD3*, Yanmei Xu, PhD4*, John Bauman5*, Melanie Baccus, RN6*, Jeanne Connor, RN, OCN2*, Jorge E. Cortes7 and Hagop M. Kantarjian1

1Leukemia, MD Anderson Cancer Center, Houston, TX
2University of Alabama at Birmingham, Birmingham, AL
3Oncology Clinical Development, GlaxoSmithKline, Collegeville, PA
4Oncology Biometrics, GlaxoSmithKline, Collegeville, PA
5Biopharmaceutical Unit, GlaxoSmithKline, King of Prussia, PA
6Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, TX
7The University of Texas MD Anderson Cancer Center, Houston, TX

Poster Board Number: III-60
In Vitro Efficacy of a Novel Liposomal Formulation of a Protein Kinase C Inhibitor In the Treatment of Acute Myeloid Leukemia

Kuan Boone Tan*, Leong Uung Ling* and Gigi Ngar Chee Chiu, PhD*

Department of Pharmacy, National University of Singapore, Singapore, Singapore

Poster Board Number: III-61
Apoptotic Blebs From Leukemic Cells as a Source of Tumor Associated Antigen for Monocyte-Derived Dendritic Cell Loading

Jurjen M Ruben, MSc1*, Hetty J Bontkes, PhD1*, Theresia M. Westers, PhD1*, Willemijn van Den Ancker, MSc1*, Gert Ossenkoppele, MD, PhD2, Tanja D de Gruijl, PhD3* and Arjan A. Van de Loosdrecht, MD, PhD4

1Department of Hematology, VU University Medical Center, Amsterdam, Netherlands
2Hematology, VU University Medical Center, Amsterdam, Netherlands
3Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands
4Department of Hematology, Cancer Center Amsterdam, V-ICI, VU University Medical Center, Amsterdam, Netherlands

Poster Board Number: III-62
Leukotoxin (LeukotheraTM), a Targeted Therapy for Hematological Malignancies

Scott C. Kachlany, PhD1*, Amy Le1* and Benjamin A Belinka Jr., Ph.D.2*

1Oral Biology, UMDNJ, Newark, NJ
2Actinobac Biomed, Inc., North Brunswick, NJ

Poster Board Number: III-63
A Phase I/II Study Combining Sunitinib with Standard Ara-C/Daunorubicin Chemotherapy In Patients 60 Years or Older with FLT3 Mutated AML

Walter Fiedler, MD1, Jürgen Krauter, MD2*, Katharina Götze3*, Helmut R. Salih, MD4, Carsten Bokemeyer, MD5*, Daniela Spaeth6*, Konstanze Döhner7*, Hartmut Döhner, MD8* and Richard F. Schlenk, MD9

1Hubertus Wald University Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
2Hematology / Oncology and Transplantation, Hannover Medical School, Hannover, Germany
3Medical Clinic III, Klinikum Rechts der Isar der Technischen Universität München, Munich
4Eberhard Karls University of Tübingen, Tuebingen, Germany
5Hematology and Oncology, University Hospital Eppendorf, Hamburg, Germany
6Internal Medicine III, University Hospital of Ulm, Ulm, Germany
7Dept. Internal Medicine III, University Ulm, Ulm, Germany
8Universitätsklinikum Ulm, Ulm, Germany
9University Hospital of Ulm, Ulm, Germany

Poster Board Number: III-64
Update of a Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies

Edward D. Ball, M.D.1, Bruno C. Medeiros, MD2*, Larissa Balaian, PhD3, Tracy Roque3*, Sue Corringham, R.N.3*, Richa Rajwanshi2*, Steven Coutre2*, Jason R Gotlib, MD, MS2*, Asad Bashey, MD, PhD4 and Karen Messer, PhD3*

1Moores UCSD Cancer Center, La Jolla, CA
2Stanford University School of Medicine, Stanford, CA
3Moores UCSD Cancer Center, Univ. of California at San Diego, La Jolla, CA
4BMT Group of Georgia, Atlanta, GA

Poster Board Number: III-65
Phase II Study of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) In Patients with Advanced Acute Leukemias

Ivana Gojo, MD1, Alison R. Walker, MD2, Maureen Cooper, MD3, Eric J Feldman, MD4, Swaminathan Padmanabhan, MBBS, MS5*, Maria R Baer, MD6, Jennifer Poon, PharmD7*, Karen Small, BSN7*, Da Zhang, MS7*, Mariola Sadowska, PhD8* and Rajat Bannerji, MD, PhD7*

1University of Maryland Greenebaum Cancer Center, Baltimore, MD
2The Ohio State University Comprehensive Cancer Center, Columbus, OH
3Hematology/Oncology, St. Francis Medical Group, Indianapolis, IN
4Division of Hematology and Medical Oncology, Cornell Medical Center, New York, NY
5CTRC at the University of Texas Health Science Center, The Institute for Drug Development, San Antonio, TX
6Greenebaum Cancer Center, University of Maryland, Baltimore, MD
7Merck & Co., Kenilworth, NJ
8Physiology and Experimental Therapeutics, University of Maryland, Baltimore, MD

Poster Board Number: III-66
A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML)

Daniel A Pollyea, MD, Holbrook E Kohrt, MD, Leonel Gallegos, MD*, Caroline Berube, MD, Steven Coutre, MD*, Jason Gotlib, M.D., M.S.*, Michaela Liedtke, MD, Beverly S. Mitchell, MD and Bruno C. Medeiros, MD*

Divisions of Hematology and Oncology and Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA

Poster Board Number: III-67
Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3-ITD Positive AML In Vitro and In Vivo

Andrew S Moore1*, Amir Faisal2*, Vassilios Bavetsias3*, Chongbo Sun3*, Butrus Atrash3*, Melanie Valenti3*, Alexis de Haven Brandon3*, Sian Avery3*, Florence I Raynaud3*, Paul Workman3*, Andrew DJ Pearson3*, Julian Blagg3*, Suzanne A Eccles3* and Spiros Linardopoulos3*

1Section of Paediatric Oncology, The Institute of Cancer Research, Sutton, United Kingdom
2Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, Sutton, United Kingdom
3Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom

Poster Board Number: III-68
High Complete Remission (CR) Rates and Reduced Early Mortality with High Dose Ara-c (HiDAC) and Mitoxantrone (MITO) Induction Chemotherapy for Older (age>60) High Risk Patients with Acute Myeloid Leukemia (AML)Clinically Relevant Abstract

Muthalagu Ramanathan, MD1, Zheng Zhou, MD1*, Jan Cerny, MD, PhD2, Glen D Raffel, M.D, Ph.D.1, Laura J Petrillo-Deluca, PA-C1*, William V Walsh, MD1, Venu Bathini, MD1, Micheal Vail1*, Karen Smethers1*, Bruce Woda, MD3, Patricia Miron, MD3*, Alan G. Rosmarin, MD1 and Rajneesh Nath, MD1

1University Campus Hematology, UMass Memorial Medical Center, Worcester, MA
2Department of Medicine, Division of Hematology/Oncology, UMass Memorial Medical Center, Worcester, MA
3Pathology, UMass Memorial, Worcester, MA

Poster Board Number: III-69
Assessment of DOT1L as a Therapeutic Target In Acute Leukemia

Stephanie Y Jo1*, Eric M Granowicz1* and Jay L. Hess, MD, PhD2

1Pathology, University of Michigan Medical School, Ann Arbor, MI
2Pathology Dept., University of Michigan, Ann Arbor, MI

Poster Board Number: III-70
Phase I Study of the Oral Histone Deacetylase Inhibitor SB939 In Patients with Advanced Hematologic Malignancies

Guillermo Garcia-Manero, MD1, Charles Chuah, MBChB, FRCPE, MD2*, George Wilding3*, Julie Chang, MD4, Srdan Verstovsek, MD, PhD1, Stefan Faderl, MD1, Hagop M. Kantarjian, MD1, Kantharaj Ethirajulu5* and Joy Zhu6*

1Department of Leukemia, MD Anderson Cancer Center, Houston, TX
2Hematology, Singapore General Hospital, Singapore, Singapore
3Carbone Cancer Center, University of Wisconsin, Madison, WI
4University of Wisconsin, Madison, WI
5Preclinical Development (Pharmokinetics and Drug Metabolism), S*BIO, Singapore 117 528
6Global Clinical Development, S*BIO, Redwood City, CA

Poster Board Number: III-71
Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML)

William Blum, MD, Rebecca B. Klisovic, MD, Ramiro Garzon, MD, Alison Walker, MD, Sebastian Schwind, MD*, Shujun Liu, PhD*, Larry Schaaf, PhD*, Celia Garr, RN*, Steven M. Devine, MD, Michael R. Grever, MD, John C. Byrd, MD and Guido Marcucci, MD

The Ohio State University Comprehensive Cancer Center, Columbus, OH

Poster Board Number: III-72
A Phase I/II Trial of the Potent Hsp90 Inhibitor STA-9090 Administered Once Weekly In Patients with Advanced Hematologic Malignancies

Jeffrey E. Lancet, MD1, B. Douglas Smith, MD2, Robert Bradley3*, Rami S. Komrokji, MD4, Florentina Teofilovici, MD3* and David A. Rizzieri, MD5

1Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL
2at Johns Hopkins, Kimmel Cancer Center, Baltimore, MD
3Medical, Synta Pharmaceuticals Corp., Lexington, MA
4Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
5Division of Cellular Therapy, Duke University Medical Center, Durham, NC

Poster Board Number: III-73
Long-Term WT1 Peptide Vaccination Over 7 Years for 3 AML Patients with Molecular Relapse

Haruo Sugiyama, MD, PhD1, Akihiro Tsuboi1*, Yoshihiro Oka, MD, PhD1*, Taiichi Kyo2*, Yuuta Katayama2*, Elisseeva Olga1*, Manabu Kawakami3*, Naoki Hosen1*, Sumiyuki Nishida1*, Soyoko Morimoto1*, Ayako Murao1*, Hiroko Nakajima1*, Ichiro Kawase4*, Yusuke Oji, MD, PhD1* and Hiroo Dohy2*

1Osaka University Graduate School of Medicine, Suita, Japan
2Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital, Hiroshima, Japan
3Nissay Hospital, Osaka, Japan
4Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino, Japan

Poster Board Number: III-74
Preliminary Clinical, Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of the Safety Run In Part of a Phase II Trial of the Orally Available MEK-Inhibitor MSC1936369 In Patients with Advanced Hematological Malignancies

Farhad Ravandi, MD1, Arnaud Pigneux, MD, PhD2*, Douglas Smith, MD3*, Hervé Dombret4*, Xavier Thomas, MD, PhD5*, Hagop M. Kantarjian, MD6, Jorge E. Cortes6, Daniel J DeAngelo, MD, PhD7*, Keith W. Pratz, MD8, Ekaterine Asatiani, MD9, Athos Gianella-Borradori, MD9, Blandine Longerey9* and Jean-Luc Harousseau10*

1The University of Texas, M. D. Anderson Cancer Center, Houston, TX
2Hôpital du Haut-Lévèque, Pessac, France
3Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, MD
4Hôpital Saint-Louis, Paris, France
5Hôpital Edouard Herriot, Lyon, France
6The University of Texas, M.D. Anderson Cancer Center, Houston, TX
7Dana-Farber Cancer Institute, Boston, MA
8Oncology, Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, MD
9Merck Serono SA, Geneva, Switzerland
10Hôpital Hotel Dieu, Nantes, France

Poster Board Number: III-75
Open-Label, Multi-Center Phase I Dose Escalation Study with Lenalidomide In Patients with Acute Myeloid Leukemia

Marie-Luise Huetter, MD1*, Walter Fiedler, M.D.2, Andrea Kuendgen, MD3*, Juergen Krauter, MD4*, Marie von Lilienfeld-Toal5*, Sabine Kayser, MD1*, Heidi Rafler1*, Hartmut Doehner, MD1* and Richard F. Schlenk, MD1

1Internal Medicine III, University Hospital Ulm, Ulm, Germany
2Hubertus Wald University Cancer Center, Department of Hematology and Oncology with sections Pneumonology and BMT, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
3Departmut of Hematology and Oncology, University hospital Düsseldorf, Düsseldorf, Germany
4Klinik für Hämostasiologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Hannover, Germany
5Department of Internal Medicine III, University Hospital of Bonn, Bonn, Germany

Poster Board Number: III-76
Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS

Marina Konopleva, MD, PhD1, Donna E. Hogge, MD, PhD2, David A. Rizzieri, MD3, Thomas P. Cirrito, PhD4*, Jen Sing Liu, PhD5*, Steven M. Kornblau, MD6, Margarite Grable7*, Il-Ran Hwang8*, Gautam Borthakur, MD1, Allison Mankin7*, Carol Bivins1*, Guillermo Garcia-Manero, MD1, Tapan Kadia, MD1, David Harris, BS9*, Farhad Ravandi, MD1, Michael Andreeff, MD, PhD8, Jorge E. Cortes1, Robert Niecestro, PhD4*, Ivan Bergstein, MD4*, Hagop M. Kantarjian, MD1 and Arthur E. Frankel, MD7*

1Leukemia, M.D. Anderson Cancer Center, Houston, TX
2Division of Hematology and Leukemia/BMT, University of British Columbia, Vancouver, BC, Canada
3Division of Cellular Therapy, Duke University Medical Center, Durham, NC
4Stemline Therapeutics, New York, NY
5Scott & White Memorial Hospital, Temple, TX
6Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX
7Scott & White Memorial Hospital and Clinic, Temple, TX
8Stem Cell Transplantation, M.D. Anderson Cancer Center, Houston, TX
9Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Poster Board Number: III-77
A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML

Andrew H Wei, MBBS, PhD1, Sonali Sadawarte2*, John Catalano, MBBS FRACP FRCPA3, Robert Hills, MA, MSc, DPhil4, Sharon Avery, MBBS5, Sushrut S. Patil, FRACP FRCPA6, Alan K Burnett, MD7* and Andrew Spencer, MD8

1Clinical Hematology, The Alfred Hospital, Monash University, Melbourne, Australia
2Clinical Hematology, Alfred Hospital, Monash University, Melbourne, Australia
3 Haematology/Oncology, Peninsula Private Hospital , Frankston, Australia
4Haematology, Cardiff University, Welsh School of Medicine, Cardiff, United Kingdom
5Dept of Haematology, Alfred Hospital, Melbourne, Australia
6Bone Marrow Trans., The Alfred Hosp., Melbourne, VIC, Australia
7Dept of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom
8Hematology, The Alfred Hospital, Melbourne, Australia

Poster Board Number: III-78
MDM2 Inhibitor Nutlin-3a Triggers Autophagic Cell Death In Addition to Apoptosis In Leukemia Cell Lines with Wild-Type p53

Seshagiri Duvvuri1*, Vivian Ruvolo2*, Duncan H. Mak, M.S.1*, Kensuke Kojima, MD, PhD1*, Marina Konopleva, MD, PhD3, Michael Andreeff, M.D., Ph.D.4 and Gautam Borthakur5

1Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX
2Section of Molecular Hematology and Therapy, Department of Leukemia, MD Anderson Cancer Center, Houston, TX
3Section of Molecular Hematology & Therapy, Department of Stem Cell Transplantation & Cellular Therapy; Department of Leukemia, MD Anderson Cancer Center, Houston, TX
4Section of Molecular Hematology & Therapy, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
5Leukemia, MD Anderson Cancer Center, Houston, TX

Poster Board Number: III-79
Clinical  Activity of Azacitidine In Combination with the Oral mTOR Inhibitor Everolimus (RAD001) In Relapsed and Refractory AML: Interim Analysis of a Phase Ib/II Study

Andrew H Wei, MBBS, PhD1, Sonali Sadawarte, MBBS, MD, DM2*, John Catalano, MBBS FRACP FRCPA3, Anthony P. Schwarer, MD4, Sharon Avery, MBBS5, Sushrut S. Patil, FRACP FRCPA6 and Andrew Spencer, MD7

1Clinical Hematology, The Alfred Hospital, Monash University, Melbourne, Australia
2Clinical Hematology, Alfred Hospital, Monash University, Melbourne, Australia
3 Haematology/Oncology, Peninsula Private Hospital , Frankston, Australia
4Haematology, Alfred Hospital, Melbourne, Australia
5Dept of Haematology, Alfred Hospital, Melbourne, Australia
6Bone Marrow Trans., The Alfred Hosp., Melbourne, VIC, Australia
7Hematology, The Alfred Hospital, Melbourne, Australia

Poster Board Number: III-80
The Novel Fluoropyrimidine FdUMP[10] Is Highly Active Against Acute Myeloid Leukemia

Timothy Pardee, MD, PhD1, Evan Gomes, PhD2*, Jamie Jennings-Gee, PhD3*, David L. Caudell, DVM, PhD4 and William Gmeiner, PhD3*

1Hem./Onc., Wake Forest University, Winston-Salem, NC
2Orlando Cancer Research Institute (Dept 6114), M.D. Anderson Cancer Center, Orlando, FL
3Cancer Biology, Wake Forest University, Winston-Salem, NC
4College of Veterinary Medicine Pathobiology, Virginia Tech, Blacksburg, VA

Poster Board Number: III-81
Mitoxantrone Improves the Outcome of Children with Central Nervous System (CNS) Involvement at First Relapse of Acute Lymphoblastic Leukemia (ALL)-Results of the International ALLR3 Study

Ashish Narayan Masurekar1*, Catriona Anne Parker1*, Satarupa Choudhuri2*, Carly Leighton2*, Jeremy Hancock3*, Rosemary Sutton, PhD4*, Anthony V. Moorman5, Phil Ancliff6*, Mary Morgan, MD7*, Nicholas Goulden8*, Nina Green9*, Tamas Revesz, MD, PhD, FRACP10*, Peter Hoogerbrugge, MD, PhD11, Philip Darbyshire12*, Sharon Love13* and Vaskar Saha1

1Children's Cancer Group, University of Manchester, Manchester, United Kingdom
2The Christie NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom
3Bristol Genetics Laboratory, Bristol, United Kingdom
4Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, Sydney, Australia
5Northern Institute of Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
6Great Ormond Street Hospital
7Dept of Haematology/Oncology, Southampton University Hospitals NHS Trust, Hampshire, United Kingdom
8Paediatric Haematology, Great Ormond Street Hospital, London, United Kingdom
9Youth and Women's Health Service
10Haematology Department, SA Pathology, North Adelaide, Australia
11Academic Hospital Nijmegen, Nijmegen, Netherlands
12Birmingham Children's Hospital
13Centre for Statistics, University of Oxford

Poster Board Number: III-82
Adaptation of a Xenograft AML Model to Evaluate Chemotherapeutic Efficacy In Vivo

Mark Wunderlich, M.S.1*, Fu-Sheng Chou, M.D.1*, Mahesh Shrestha, MS1*, Benjamin Mizukawa, M.D.2* and James C. Mulloy, PhD1

1Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
2Hematology and Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Poster Board Number: III-83
All-Trans-Retinoic Acid (ATRA) Causes Extensive Differentiation In the NPM Mutant, Non-APL Leukemic Cell Line OCI-AML3

Matthew A. Kutny, MD1, Steven J. Collins, MD2, Keith Loeb, MD, PhD1*, Roland B. Walter, MD, PhD1 and Soheil Meshinchi, MD, PhD1

1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
2Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA

Poster Board Number: III-84
Antileukemic Activity of the HSP70 Inhibitor Pifithrin-µ

Martin Kaiser1*, Andrea Kuehnl2*, Jutta Ortiz-Tanchez, MS2*, Ouidad Benlasfer2*, Cornelia Schlee, MS3*, Sandra Heesch2*, Eckhard Thiel2 and Claudia Baldus2*

1Division of Molecular Pathology, The Institute of Cancer Research, Sutton, United Kingdom
2Department of Hematology and Oncology, Charité - University Hospital Berlin, Berlin, Germany
3Hematology and Oncology, Charité, University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany

Poster Board Number: III-85
A Phase I Study of ENMD-2076 In Patients with Relapsed or Refractory Leukemia

Karen W.L. Yee, MD1, Hsaio-Wei Tina Chen2*, Joseph Brandwein, MD, FRCPC1, Sue Chow2*, Deborah Sanfelice2*, David Hedley, MD1*, Vikas Gupta, MD, FRCP, FRCPath3, Aaron Schimmer, MD, PhD3, Carolyn Fowler Sidor, MD4, Graham Fletcher5*, Jamie Arnott6*, Mark Bray5*, Mark D. Minden, MD, PhD1 and Andre Schuh, MD, FRCPC1*

1Division of Medical Oncology & Hematology, Princess Margaret Hospital, Toronto, ON, Canada
2Princess Margaret Hospital, Toronto, ON, Canada
3Medical Oncology & Hematology, Princess Margaret Hospital, Toronto, ON, Canada
4EntreMed, Inc., Chapel Hill, NC
5EntreMed, Inc., Toronto, ON, Canada
6EntreMed, Inc., Durham, NC

Poster Board Number: III-86
ABT-737 Targets Leukemic Stem Cells In Mouse Models of Mutant NRASD12/hBCL-2- Mediated Acute Myeloid Leukemia Progression with Increased Survival

Rose Ann Padua, PhD1, Stephanie Beurlet, DMV1*, Patricia Krief, PhD1*, Nader Omidvar, PhD2*, Carole Le Pogam, BSc1*, Didier Auboeuf, PhD3*, Pierre de la Grange, PhD4*, Annie Soulie1*, Anne Janin, MD, PhD5, Maria-Elena Noguera, MD6*, Pascal Merlet, MD7*, Laure Sarda-Mantel, MD, PhD8*, Pierre Fenaux, MD, PhD9, Marina Konopleva, MD, PhD10, Michael Andreeff, MD, PhD10, Andrea Tu, PhD11*, Phoebe Yang, PhD11*, Alice C. Fan, MD12*, Scott C. Kogan, MD13, Irving L. Weissman, MD14, Dean W. Felsher, MD, PhD12*, Marika Pla, PhD1*, Robert West, PhD15* and Christine Chomienne, MD, PhD1*

1Inserm UMR-S940, Institut Universitaire d'Hématologie, Paris, France
2Haematology, Cardiff University School of Medicine, Cardiff, France
3Inserm U590, Cheney A 4e Etage, 69373 Lyon, France
4GenoSplice Technology, Institut Universitaire d'Hematologie, Paris, France
5Inserm UMR-S728, Institut Universitaire d'Hématologie, Paris, France
6Hematology, Hôpital Saint-Louis, Paris, France
7Institut Universitaire d'Hematologie, Paris
8Nuclear Medicine, Hôpital Bichat, Paris
9Service d'Hématologie Clinique, Hôpital Avicenne Université Paris XIII, Bobigny, France
10The University of Texas, M. D. Anderson Cancer Center, Houston, TX
11Cell Biosciences Inc., Santa Clara, CA
12Medicine, Stanford University Cancer Center, Stanford, CA
13Laboratory Medicine, University of California, San Francisco, San Francisco, CA
14Stanford University School of Medicine, Stanford, CA
15Wales Heart Institute, Cardiff University School of Medicine, Cardiff, United Kingdom

Poster Board Number: III-87
Effective and Non-Cytotoxic p53 Independent Epigenetic-Differentiation Therapy In Xeno-Transplant Models of Human Acute Myeloid Leukemia

Kwok Peng Ng, PhD1, Quteba Ebrahem, MD2*, Soledad Negrotto, PhD2*, Reda Mahfouz, MD2*, Kevin A. Link, PhD3, Zhenbo Hu, MD1, Xiaorong Gu, PhD2*, Anjali S. Advani, MD1, Matt Kalaycio, MD1, Mikkael A. Sekeres, MD, MS4, Edward A. Copelan, MD5, Jaroslaw P. Maciejewski, MD, PhD2, James C. Mulloy, PhD6 and Yogenthiran Saunthararajah, MD2

1Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
3Dept. of Experimental Hem, Cincinnati Children's Hospital, Cincinnati, OH
4Cleveland Clinic, Taussig Cancer Center, Cleveland, OH
5Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH
6Dept. of Experimental Hem., Cincinnati Children's Hospital, Cincinnati, OH

Poster Board Number: III-88
A Phase Ib Dose-Finding Study of Oral Panobinostat In Combination with Cytarabine (ara-C) and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia (AML)

Jürgen Krauter, MD1*, Richard F. Schlenk, MD2, Markus Schaich, MD3*, Didier Bouscary, MD4*, Hervé Dombret5*, Ivo J. Winiger, MD6, Margaret Squier, MD, PhD7*, Bourras-Rezki Bengoudifa6* and Oliver G. Ottmann, MD8

1Hannover Medical School, Hannover, Germany
2University Hospital of Ulm, Ulm, Germany
3Universitätsklinikum Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany
4Hôpital Cochin, Paris, France
5Hematology Department, Hospital Saint-Louis APHP University Paris VII, Paris, France
6Novartis Pharma AG, Basel, Switzerland
7Novartis Pharmaceuticals Corporation, East Hanover, NJ
8Goethe University, Frankfurt, Germany

Poster Board Number: III-89
The Synergistic Effect of DNA Methylation Inhibitor 5-Azacytidine and Bcl-2 Signaling Blockade ABT-737 Combination Treatment Induce Apoptosis In AML

Yuexi Shi1*, Twee Tsao2*, Hongbo Lu, MMSC1*, Sergej Konoplev, MD, PhD3, Wendy D. Schober2*, Michael Andreeff, MD, PhD2 and Marina Konopleva, MD, PhD4

1Section of Molecular Hematology & Therapy, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
2Stem Cell Transplantation, M.D. Anderson Cancer Center, Houston, TX
3Hematopathology, M.D. Anderson Cancer Center, Houston, TX
4Leukemia, M.D. Anderson Cancer Center, Houston, TX

Poster Board Number: III-90
Combination Therapy with Entinostat (MS-275) and GM-CSF to Enhance Differentiation In Myeloid Malignancies

Cho Eunpi, M.D.1*, William Matsui, MD2, Jeanne Kowalski, PhD3, Hua-Ling Tsai, MS4*, Richard J. Jones5 and B. Douglas Smith, MD6

1Oncology, Johns Hopkins University, Baltimore, MD
2Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD
3Oncology Biostatistics, Johns Hopkins University, Baltimore, MD
4Oncology Biostatistics, Johns Hopkins University School of Medicine
5Johns Hopkins University, Baltimore, MD
6at Johns Hopkins, Kimmel Cancer Center, Baltimore, MD

Poster Board Number: III-91
Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status--Based Treatment Stratification

Bruno C. Medeiros, MD1, Holbrook E Kohrt, MD2, Richa Rajwanshi3*, Jason Gotlib, M.D., M.S.4*, Steven E. Coutre, MD1, Michaela Liedtke, MD4, Caroline Berube, MD2, Melody Zhang4*, Daniel A. Arber, MD5 and James L. Zehnder, M.D.6*

1Divisions of Hematology and Oncology and Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA
2Hematology, Stanford University School of Medicine, Stanford, CA
3Stanford U School of Medicine, Stanford, CA
4Division of Hematology, Stanford University School of Medicine, Stanford, CA
5Dept. of Clinical Laboratory, Stanford Univ. Medical Center, Stanford, CA
6Department of Pathology, Stanford University School of Medicine, Stanford, CA

Poster Board Number: III-92
Sorafenib Monotherapy Is Effective In Relapsed and RefractoryFlt3-ITD Positive Acute Myeloid Leukemia, Particularly After Allogenic Stem Cell Transplantation

Stephan Metzelder, MD1*, Anemone Finck, MD2*, Martin F. Fey, MD3*, Sebastian Scholl, MD4*, Matthias Kröger, MD5*, Andreas Reiter, MD6*, Helmut R. Salih, MD7, Katharina Götze, MD8*, Ralf Georg Meyer, MD9*, Aristoteles Giagounidis, MD10, Wolfram Brugger, MD11*, Matthias Vöhringer, MD12*, Lothar Müller, MD13*, Linn Yeh Ching, MD14*, Peter Dreger, MD, PhD15*, Masanori Mori, MD16*, Nadezda Basara, MD17, Kerstin Schaefer-Eckart18*, Beate Schultheis, MD19*, Claudia Baldus, MD20*, Andreas Neubauer, MD21 and Andreas Burchert, MD22

1Hematology/Oncology/Immunology, Universitätsklinikum Giessen und Marburg GmbH, Marburg, Germany
2Hematology/Oncology, University of Freiburg, Freiburg, Germany
3Medical Oncology Inselspital, Berne, Switzerland
4Hematology/Oncology, Universitätsklinikum Jena, Jena
5Onkologische Schwerpunktpraxis Bremerhaven, Bremerhaven
6III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany
7Eberhard Karls University of Tübingen, Tuebingen, Germany
8Medical Clinic III, Klinikum Rechts der Isar der Technischen Universität München, Munich
9Hematology/Oncology, University Hospital Mainz, Mainz
10Med. Klinik 2, St. Johannes Hospital, Duisburg, Germany
11Klinikum der Stadt Villingen-Schwenningen GmbH, Villingen-Schwenningen, Germany
12Internal Medicine, Oncology and Hematology, Robert Bosch Hospital Stuttgart, Stuttgart
13Onkologische Schwerpunktpraxis Leer-Emden
14Haematology, Singapore General Hospital
15Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
16Hematology and Oncology, University of Vermont, Burlington, VT
17Hematology, Oncology and Hemostaseology, University Clinical Center, Leipzig, Germany
18Bone Marrow Transplantation, North Hospital Nuernberg, Nuernberg, Germany
19Medizinische Klinik III - Hematology/Oncology, Marienhospital Herne
20Department of Hematology and Oncology, Charité, University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany
21Department of Hematology, Oncology and Immunology, University Hospital of Marburg, Marburg, Germany
22Department of Hematology, Oncology and Immunology, Philipps University Marburg, Marburg, Germany

Poster Board Number: III-93
Tipifarnib Is Well Tolerated as Maintenance Therapy In Acute Myeloid Leukemia  (AML).  Significant, but Non-Fatal, Hematologic Toxicity Not Ameliorated by Dose Reduction. Preliminary Results of the Phase III Intergroup Trial E2902

Selina M. Luger, MD1, Xiaopan Yao, PhD, MS2*, Elisabeth Paietta, PhD3, Rhett Ketterling4*, Witold Rybka, MD5, Mark R. Litzow, MD6, Jacob M. Rowe, MD7, Richard Larson, M.D.8* and Martin S. Tallman, MD9

1University of Pennsylvania, Philadelphia, PA
2Dana-Farber Cancer Institute, Boston, MA
3North Division, Montefiore Medical Center, Bronx, NY
4Mayo Clinic, Rochester
5Div. of Hematology/Oncology, Penn State Hershey Cancer Institute, Hershey, PA
6Hematology, Mayo Clinic, Rochester, MN
7Hematology and Bone Marrow Transplantation, Rambam Medical Center, Technion, Haifa, Israel
8University of Chicago, Chicago, IL
9Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY

Poster Board Number: III-94
Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine

Gesine Bug, MD, PhD1*, Richard F. Schlenk, MD, PhD2, Carsten Müller-Tidow, MD, PhD3*, Michael Lübbert, MD, PhD4*, Alwin Krämer, MD, PhD5*, Frank Fleischer6*, Tillmann Taube, MD6, Oliver G. Ottmann, MD, PhD7 and Hartmut Doehner, MD, PhD2*

1Department of Medicine, Hematology/Oncology, Goethe University, Frankfurt, Germany
2Internal Medicine III, University of Ulm, Ulm, Germany
3University Hospital Muenster, Muenster, Germany
4Department of Hematology and Oncology, University of Freiburg, Freiburg, Germany
5Medizinische Klinik V, University Hospital of Heidelberg, Heidelberg, Germany
6Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
7Medizinische Klinik II - MRD-Labor, Universitaetsklinik Frankfurt, Frankfurt, Germany

Poster Board Number: III-95

*signifies non-member of ASH